|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: STXBP5L |
Gene summary for STXBP5L |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | STXBP5L | Gene ID | 9515 |
| Gene name | syntaxin binding protein 5L | |
| Gene Alias | LLGL4 | |
| Cytomap | 3q13.33 | |
| Gene Type | protein-coding | GO ID | GO:0006810 | UniProtAcc | B4DKF6 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 9515 | STXBP5L | CCI_1 | Human | Cervix | CC | 2.81e-21 | 1.75e+00 | 0.528 |
| 9515 | STXBP5L | CCI_3 | Human | Cervix | CC | 2.30e-55 | 2.23e+00 | 0.516 |
| 9515 | STXBP5L | HTA12-15-2 | Human | Pancreas | PDAC | 9.49e-17 | 1.04e+00 | 0.2315 |
| 9515 | STXBP5L | HTA12-16-2 | Human | Pancreas | PDAC | 1.71e-02 | 9.14e-01 | 0.0535 |
| 9515 | STXBP5L | HTA12-23-1 | Human | Pancreas | PDAC | 7.33e-25 | 1.54e+00 | 0.3405 |
| 9515 | STXBP5L | HTA12-25-1 | Human | Pancreas | PDAC | 9.43e-22 | 1.35e+00 | 0.313 |
| 9515 | STXBP5L | HTA12-26-1 | Human | Pancreas | PDAC | 7.79e-45 | 1.63e+00 | 0.3728 |
| 9515 | STXBP5L | HTA12-29-1 | Human | Pancreas | PDAC | 1.48e-110 | 1.73e+00 | 0.3722 |
| 9515 | STXBP5L | HTA12-30-1 | Human | Pancreas | PDAC | 5.66e-08 | 1.48e+00 | 0.3671 |
| 9515 | STXBP5L | HTA12-32-1 | Human | Pancreas | PDAC | 1.71e-15 | 1.77e+00 | 0.3624 |
| 9515 | STXBP5L | HTA12-9-1 | Human | Pancreas | PDAC | 1.32e-03 | 3.60e-01 | 0.1532 |
| Page: 1 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Cervix |  | CC: Cervix cancer |
| HSIL_HPV: HPV-infected high-grade squamous intraepithelial lesions | ||
| N_HPV: HPV-infected normal cervix |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:00171574 | Cervix | CC | regulation of exocytosis | 39/2311 | 202/18723 | 2.90e-03 | 1.93e-02 | 39 |
| GO:00068873 | Cervix | CC | exocytosis | 59/2311 | 352/18723 | 8.74e-03 | 4.48e-02 | 59 |
| Page: 1 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| STXBP5L | SNV | Missense_Mutation | c.1631N>A | p.Ser544Asn | p.S544N | Q9Y2K9 | protein_coding | tolerated(0.18) | probably_damaging(0.977) | TCGA-A2-A0CX-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | adriamycin | SD | |
| STXBP5L | SNV | Missense_Mutation | c.1258N>C | p.Asp420His | p.D420H | Q9Y2K9 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-AC-A23H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD | |
| STXBP5L | SNV | Missense_Mutation | rs372264577 | c.3086N>A | p.Arg1029Gln | p.R1029Q | Q9Y2K9 | protein_coding | deleterious(0) | probably_damaging(0.994) | TCGA-AN-A046-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| STXBP5L | SNV | Missense_Mutation | c.3356N>T | p.Pro1119Leu | p.P1119L | Q9Y2K9 | protein_coding | deleterious(0) | benign(0.015) | TCGA-E9-A1R7-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | fareston | SD | |
| STXBP5L | SNV | Missense_Mutation | novel | c.858N>G | p.Phe286Leu | p.F286L | Q9Y2K9 | protein_coding | tolerated(0.76) | benign(0.228) | TCGA-C5-A1M5-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | PD |
| STXBP5L | SNV | Missense_Mutation | c.1969G>C | p.Gly657Arg | p.G657R | Q9Y2K9 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-C5-A2LX-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | SD | |
| STXBP5L | SNV | Missense_Mutation | c.3070G>A | p.Asp1024Asn | p.D1024N | Q9Y2K9 | protein_coding | tolerated(0.19) | probably_damaging(0.998) | TCGA-C5-A2LX-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | SD | |
| STXBP5L | SNV | Missense_Mutation | c.1198G>C | p.Glu400Gln | p.E400Q | Q9Y2K9 | protein_coding | tolerated(0.05) | probably_damaging(0.99) | TCGA-C5-A7CO-01 | Cervix | cervical & endocervical cancer | Female | >=65 | I/II | Chemotherapy | cisplatin | SD | |
| STXBP5L | SNV | Missense_Mutation | rs761215215 | c.3149N>A | p.Arg1050Gln | p.R1050Q | Q9Y2K9 | protein_coding | deleterious(0) | probably_damaging(0.994) | TCGA-C5-A8XH-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
| STXBP5L | SNV | Missense_Mutation | novel | c.3208A>G | p.Thr1070Ala | p.T1070A | Q9Y2K9 | protein_coding | tolerated(0.23) | probably_damaging(0.992) | TCGA-5M-AAT6-01 | Colorectum | colon adenocarcinoma | Female | <65 | III/IV | Unknown | Unknown | PD |
| Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |